Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SEL201 |
Synonyms | |
Therapy Description |
SEL201 selectively inhibits MNK1 and MNK2, resulting in inhibition of tumor cell growth and metastasis (PMID: 29035277, PMID: 31903169). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SEL201 | MNK1/2 Inhibitor 3 | SEL201 selectively inhibits MNK1 and MNK2, resulting in inhibition of tumor cell growth and metastasis (PMID: 29035277, PMID: 31903169). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT L576P | melanoma | sensitive | SEL201 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cells harboring KIT L576P in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277). | 29035277 |
KIT D820Y | melanoma | sensitive | SEL201 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cell lines harboring KIT D820Y in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277). | 29035277 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|